Quarterly Report
Brisbane, April 19, 2018 AEST (ABN Newswire) - Anatara Lifesciences (
ASX:ANR) today released its Appendix 4C financial report for the quarter ending 31st March 2018.
Anatara Lifesciences is pleased to advise a neutral cash flow for the quarter ending 31st March 2018 and an updated cash balance of $8.76 million as reported in the attached March Appendix 4C.
Anatara Chairman, Dr Mel Bridges said, "Since listing in October 2014, the Anatara team has worked diligently on delivering its key milestones, and is focused on continuing to do so. We are pleased to maintain a strong cash position and appreciate the patience of our shareholders whilst we positively move along the path to delivering shareholder value."
To view the full report, please visit:
http://abnnewswire.net/lnk/CZ97UW6L
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
| ||
|
